News
People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...
In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Amazon says the company will join other partners including United Parcel Service and the U.S. Postal Service that regularly work alongside Amazon's last-mile delivery network. The private-equity ...
In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
5:54 PM UTC · Updated ago Boards, Policy & Regulationcategory Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results